US Stock MarketDetailed Quotes

BTAI BioXcel Therapeutics

Watchlist
  • 0.509
  • -0.062-10.80%
Close Nov 22 16:00 ET
  • 0.510
  • +0.001+0.20%
Post 20:01 ET
21.76MMarket Cap-249P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Nov 22 07:29
    NEWS
    $BioXcel Therapeutics (BTAI.US)$
    BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering
    NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the "Company") (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the pricing of an underwritten public offering of 5,600,000 shares of its common stock, par value $0.001 per share ("Comm...
    Jaguar8
    Jaguar8
    Nov 12 06:01
    NEWS
    $BioXcel Therapeutics (BTAI.US)$
    BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia
    First patient randomized in SERENITY At-Home trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia
    Received FDA feedback on protocol for TRANQUILITY In-Care trial of BXCL501 for agitation associated with Alzheimer's dementia (AAD)
    Estimated 140 ...
    Trytosaveabit
    Trytosaveabit
    Oct 15 06:21
    Update!
    $BioXcel Therapeutics (BTAI.US)$ BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of Bxcl501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder
    Jaguar8
    Jaguar8
    Sep 5 06:58
    NEWS
    $BioXcel Therapeutics (BTAI.US)$
    BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
    WJJG
    WJJG
    Jul 16 06:14
    Good news! 90% increase Q over Q
    $BioXcel Therapeutics (BTAI.US)$ …The Company expects unaudited revenue of approximately $1.1 million for the three months ended June 30, 2024, representing an increase of approximately 90% quarter over quarter and approximately 141% compared to the same period in 2023. Revenue growth was driven by an increase in contracting with psychiatric care clinics and behavioral health facilities using a small commercial team…
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data